At the same 2.4 mg weekly maintenance dose, ecnoglutide produced a 12.8% mean body weight reduction at 20 weeks against semaglutide‘s 9.5% — a gap that translated into 74% of ecnoglutide patients hitting the ≥10% loss threshold versus just 40% on the comparator. That asymmetry is the central clinical question the SLIMMER-UP-SWITCH trial was designed to answer, and the interim data presented as a late-breaking abstract at the 2026 ADA Scientific Sessions in New Orleans make it harder to dismiss ecnoglutide as a regional variation on a familiar mechanism.
The mechanistic argument matters here. Ecnoglutide is described as a cAMP-biased GLP-1 receptor agonist, meaning it preferentially activates the cyclic AMP signaling pathway rather than triggering the full suite of downstream pathways that conventional GLP-1 receptor agonists engage. The premise is that traditional full-pathway activation drives both efficacy and gastrointestinal tolerability problems simultaneously, and that selectivity can decouple them. The SLIMMER-UP-SWITCH data lend that premise direct head-to-head support for the first time: gastrointestinal safety remained favorable in the ecnoglutide arm, consistent with the earlier Phase 3 SLIMMER trial, where the discontinuation rate due to GI adverse events was 0.6% across 664 patients over 48 weeks. Whether that tolerability advantage holds at longer durations is still an open question — this interim cuts at Week 20 in a 60-week study.
The trial design carries important caveats. SLIMMER-UP-SWITCH is open-label, enrolled only in China, and the 163-patient population studied obesity at BMI ≥30 — a narrower phenotype than the broader overweight-plus-comorbidity population that earned Wegovy its 2021 FDA approval. Semaglutide’s landmark STEP 1 trial ran 68 weeks in 1,961 participants and produced −14.9% mean weight loss with lifestyle intervention — a benchmark that ecnoglutide’s Phase 3 SLIMMER data (−15.4% at 48 weeks, highest dose) roughly matches but does not yet clearly surpass in a controlled global population. Pfizer’s role as China commercialization partner also signals that near-term commercial ambitions are geographically bounded, even if the biased-agonist science is globally watched.
The single number to track from here is the Week 60 primary endpoint readout from SLIMMER-UP-SWITCH. If the separation between ecnoglutide and semaglutide at 12.8% versus 9.5% body weight loss holds or widens at trial completion, the argument for a biased-agonist regulatory filing outside China becomes structurally difficult for Sciwind and Pfizer to ignore.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
